

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-21. **(Canceled)**

22. **(Withdrawn)** A pharmaceutical composition comprising a molecule targeted to a tissue selected from the group consisting of pulmonary circulation, intestinal circulation, pulmonary airways, lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus and brain, which molecule is conjugated to a DEC-ligand, which DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, and a pharmaceutically acceptable carrier.

23. **(Withdrawn)** The pharmaceutical composition of claim 22, wherein the molecule is selected from the group consisting of an anti-cancer drug, an anti-viral drug, an antibiotic, an anti-parasitic drug, and an anti-inflammatory drug.

24-25. **(Canceled)**

26. **(Previously presented)** A vaccine for inducing an immune response comprising an antigen conjugated to an anti-human Dendritic and Epithelial Cell 205 (DEC-205) antibody or an anti-murine DEC-205 antibody reactive with a human DEC-205 protein, said human DEC-205 protein comprising an amino acid sequence as set forth in SEQ ID NO: 1.

27. **(Previously presented)** The vaccine of claim 26, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor.

28. **(Currently Amended)** The vaccine of claim 26, further comprising an ~~wherein the~~ immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

29. **(Withdrawn)** A composition to induce immune suppression comprising an autoantigen or an allergen conjugated to a DEC-ligand, wherein the DEC ligand is selected from the group consisting of a carbohydrate that binds and an anti-DEC antibody, with the proviso that the composition lack immune stimulatory agents.

30. **(Withdrawn)** The composition of claim 29, wherein the autoantigen is selected from the group consisting of myelin basic protein, collagen or a fragment thereof, DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein, and a pancreatic β -cell protein.

31-34. **(Canceled)**

35. **(Previously Presented)** A vaccine for inducing an immune response comprising an antigen conjugated to an anti-human Dendritic and Epithelial Cell 205 (DEC-205) antibody, wherein the antibody is reactive with the amino acid sequence as set forth in SEQ ID NO: 1.

36. **(Previously Presented)** A vaccine for inducing an immune response comprising an antigen conjugated to an anti-mouse Dendritic and Epithelial Cell-205 (DEC-205) antibody, wherein the antibody is reactive with the amino acid sequence as set forth in SEQ ID NO: 1.

37. **(Previously Presented)** The vaccine of any one of claims 26, 35, or 36, further comprising an immune stimulator.

38. **(Previously Presented)** The vaccine of claim 37, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

39. **(Previously Presented)** The vaccine of any one of claims 26, 35, or 36, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor.

40. **(Previously Presented)** A vaccine for inducing an immune response comprising an antigen conjugated to an antibody which binds mouse Dendritic and Epithelial Cell 205 (DEC-205) having the amino acid sequence of SEQ ID NO: 3, wherein the antibody cross reacts with human DEC-205.

41. **(Previously Presented)** The vaccine of claim 40, further comprising an immune stimulator.

42. **(Previously Presented)** The vaccine of claim 41, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

43. **(Previously Presented)** The vaccine of claim 40, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor antigen.

44. **(Previously Presented)** The method of claim 40, wherein the antigen is bound to the antibody to DEC-205 by means of a cross-linking agent.

45. **(Previously Presented)** The method of claim 40, wherein a light chain or a heavy chain of the antibody to DEC-205, and the antigen, are present on a single polypeptide chain.